12 hours ago
AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment
AstraZeneca (AZN) climbed 3.1% as Bernstein reaffirms outperform rating, citing non-oncology portfolio as undervalued driver worth 37% upside to £186 target.
The post AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment appeared first on Blockonomi.
Source: Blockonomi →Related News
- 11 hours ago
Healthcare Sector Sees Stealth Rally as Institutional Money Flows In
- 11 hours ago
BlockchAIn Digital Infrastructure (AIB) Stock Plunges 21% Following $55M Equity...
- 11 hours ago
Wall Street Tumbles as Robust Employment Data Sparks Fed Rate Hike Speculation
- 11 hours ago
FuelCell Energy (FCEL) Q2 Earnings Preview: Can the Rally Continue Past June 8?
- 11 hours ago
Salesforce (CRM) Secures FIFA World Cup 2026 Partnership as Official Supporter